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The involvement of counteractive CD8 T-cell subsets during tumor-specific immune responses
was analyzed in a syngeneic murine plasmacytoma model. CD8 Tc cells against the
immunogenic IL-10-producing BALB/c plasmacytoma ADJ-PC-5 can be easily induced by
immunization of BALB/c mice with X-irradiated ADJ-PC-5 tumor cells in vivo and in vitro.
However, the failure of recipient mice to mount a protective Tc response against the tumor
during early stages of a real or simulated tumor growth is not due to immunological ignorance,
but depends on the induction of tumor-specific tolerance, involving a population of tumor-
induced CD8 T cells that are able to inhibit the generation of tumor-specific Tc cells in a
primary ADJ-PC-5-specific MLTC, using IFN-T as a suppressive factor. Whereas most long-
term cultivated CD8 ADJ-PC-5-specific Tc lines produce type-1 cytokines on stimulation, at
least two of them, which were derived from a primary MLTC, display a type-2 cytokine
spectrum. Furthermore, the primary in vitro Tc response against ADJ-PC-5 cells shows
characteristics of a Tc2 response. The Tc response is strictly depending on tumor-derived IL-10.
CD8 Tc cells that are induced in a primary MLTC do not produce IFN- y, and the tumor-specific
Tc response is enhanced by IL-4 but suppressed by IFN-y or IL-12. In contrast, ADJ-PC-
5-specific CD8 Tc cells from immunized mice are IFN-y producing Tc cells. Since the primary
in vitro Tc response against the tumor is suppressed even by the smallest numbers of irradiated
ADJ-PC-5-specific Tc cells via IFN-% these Tc cells behave similar to the suppressive CD8
T cells that are induced during early stages of ADJ-PC-5 tumorigenesis.
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INTRODUCTION
In most cases, tumors grow in their primary hosts or
syngeneic recipients without beeing hampered by the
immune system, even if the tumor cells express
immunogenic neoantigens. The lack of apparent
immunogenicity of tumors in situ might be due to
special properties of the tumor cells, for example lack
of costimulatory molecules, downregulation of MHC
molecules, or production of immunosuppressive
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factors (Browning and Bodmer, 1992; Chen et al.,
1992; Sulizeanu, 1993), or due to intrinsic tolerance
mechanisms of the immune system (Mengersen et al.,
1975; Naor, 1979; North, 1985). Under special
experimental conditions, however, it is possible to
mount protective immune responses against tumor
cells, involving specific Tc cells or nonspecific
macrophages and NK cells. Activation of Tc cells
against tumor-specific transplantation antigens is
necessary for any kind of vaccinization strategy or for
adoptive immunotherapy against cancer. Thus, in the
context of such therapies, it is necessary to analyze
phenotypes and activation modalities of tumor-spe-
cific Tc cells and their fate in situ, in the presence of
a growing tumor. Using the highly malignant BALB/c
plasmacytoma ADJ-PC-5 as a model tumor, we
studied the regulation of tumor-specific Tc responses,
especially during early stages of tumorigenesis.
Syngeneic BALB/c mice can be protectively
immunized against this tumor by four weekly i.p.
injections with 107 X-irradiated ADJ-PC-5 cells
(Cihak et al., 1981), which leads to the activation of
tumor-specific CD8 Tc cells. Specific CD8 Tc cells
against the tumor can also be induced in vitro, in a
primary syngeneic mixed lymphocyte tumor cell
culture (MLTC) (Haubeck and K61sch, 1982). How-
ever, the growth of ADJ-PC-5 tumor cells in synge-
neic BALB/c mice is accompanied by the induction of
a subset of CD8 regulatory T cells, which are
characterized by their ability to suppress the induction
of tumor-specific CD8 Tc cells in a primary MLTC
in vitro (Haubeck and K61sch, 1982, 1986). These
suppressive T cells are induced during early stages of
tumorigenesis, when the tumor burden is small, and
possibly hold down a protective cytotoxic T-cell (Tc)
response against the tumor, even when the tumor
mass reaches an immunogenic level. Recent data
indicate that the T-cell-mediated suppressive effect in
vitro involves IFN-T as a suppressor factor, but does
not depend on IL-2 consumption (Pauels et al., 1996).
The finding that IFN-T is a suppressive factor for Tc
induction in vitro prompted us to study phenotypes
and activation modalities of ADJ-PC-5-specific Tc
cells in more detail.
RESULTS
Simulation of ADJ-PC-5 Tumor Growth in the
Peritoneal Cavity is Accompanied by the
Induction of IFN-y-Producing Suppressive CD8
T Cells
In previous studies, an in vitro protocol for the
induction of ADJ-PC-5-specific Tc cells was
developed, which is based on a primary syngeneic
MLTC (Haubeck and K61sch, 1982). As shown in
Figure (a), tumor-induced suppressive T cells can be
isolated from the peritoneal cavity of syngeneic
BALB/c mice that have been subjected to a simulated
ADJ-PC-5 tumor growth by daily i.p. injections of
exponentially increasing numbers of 60-Gy X-irra-
diated ADJ-PC-5 cells. These T cells are character-
ized by their ability to suppress the induction of a
tumor-specific Tc response from naive BALB/c
spleen cells in a primary syngeneic ADJ-PC-5-spe-
cifi MLTC in vitro. The respective suppressive T
cells have been shown previously to be CD8 and to
display no substantial cytolytic activity against ADJ-
PC-5 cells (Haubeck and K61sch, 1982, 1986). Such
suppressive cells are not found in the peritoneal cavity
of naive mice. The dominant role played by IFN-y as
a suppressive factor in this experimental system is
proven by two lines of evidence: (1) Addition of
recombinant IFN-y to a primary ADJ-PC-5-specific
MLTC substantially reduces Tc induction against the
tumor cells; see Figure l(c). (2) Addition of IFN-y-
specific monoclonal antibodies to an MLTC contain-
ing PEC from tumor-treated mice can almost com-
pletely restore Tc induction, whereas addition of
control monoclonal antibodies has no such effect; see
Figure (d).
Characterization of the ADJ-PC-5-Specific Tc
Response in a Primary MLTC
Since the primary in vitro Tc response against ADJ-
PC-5 plasmacytoma cells is suppressed by tumor-
induced CD8 regulatory T cells via IFN-T, the
effects of other exogenous and endogenous cytokines
on a primary MLTC as well as the phenotype of the
resulting Tc cells were analyzed in more detail.TC1/TC2 RESPONSES AGAINST A MURINE PLASMACYTOMA 333
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FIGURE Suppression by PEC from ADJ-PC-5-treated mice is due to IFN-y. (a) Suppressive T cells were generated by repeated i.p.
injections of exponentially increasing numbers of X-irradiated ADJ-PC-5 cells (according to Materials and Methods) and added to an ADJ-
PC-5-specifi MLTC on day 0. The resulting tumor-specific cytotoxicity was measured on day 6 by a 51Cr-release assay. The cytotoxicity
in the presence of nonadherent PEC from tumor treated mice (’--’) was compared with the cytotoxicity in the presence ofPEC from naive
mice (I--I). Control cultures were set up without PEC (Fq--[3) or without PEC and ADJ-PC-5 cells (C)--(C)). (b) Cytokine kinetics in
MLTC supernatants corresponding to part (a). Substantial amounts of IFN-y can only be detected in MLTC supernatants containing
suppressive T cells from tumor-treated mice (tum.). Samples of culture supernatants were taken at the indicated time points and assaged for
IFN-T according to Materials and Methods. (c) MLTC cultures were set up with 2 107 navie BALB/c spleen cells and 106 X-irradiated
ADJ-PC-5 cells in the presence of different concentrations IFN-y: O: no IFN-y added; I: 50 U/ml; and ’
500 U/ml. Specific cytotoxicity
was measured on day 6 of the culture period. (d) MLTC cultures were set up with (’--’) or without (F-l--E]) nonadherent PEC from tumor-
treated mice in the presence of. 20 txg/ml of an IFN-y-specific monoclonal rat IgG antibody (ce-IFN-y) or in the presence of 20 tzg/ml of
an irrelevant IgE-specific rat IgG monoclonal antibody (ce-IgE).
Beside the suppressive effect of IFN-y on Tc
induction in vitro, addition of IL-4 to a primary ADJ-
PC-5-specifi MLTC has an enhancing effect on Tc
induction, whereas addition of IL-12 is slightly
suppressive in this context (Becker et al., 1997).
Another striking difference between the primary in
vitro Tc response against ADJ-PC-5 cells and a
typical Tc response, as seen in the case of a primary
allogenic MLC, is the absolute dependence of the
tumor-specific Tc response on tumor-derived IL-10.
As shown in Figure 2, addition of IL-10-specific
monoclonal antibodies to a primary MLTC can
completely eliminate the ADJ-PC-5-specific Tc
response, whereas an allogenic controlMLC ofCBA/J
spleen cells against irradiated BALB/c spleen cells is
not affected. In addition, cytokine production ofCD8334 C. SPECHT et al.
T cells from a primary ADJ-PC-5-specific MLTC and
a primary allogenic MLC was compared on a single-
cell level by flow cytometry. As shown in Figure 3,
the percentage of CD8 T cells increases significantly
in both types of cultures as compared with unstimu-
lated control cultures, indicating that an antigen-
specific stimulation of CD8 T cells must have taken
place in both types of cultures. Despite the develop-
ment of a cytotoxic phenotype, CD8 T cells from an
ADJ-PC-5-specific MLTC differ from typical alloan-
tigen-induced CD8 Tc cells by a lack of IFN-y
production. Production of IL-4 could neither be
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FIGURE 2 Induction of ADJ-PC-5-specific Tc cells in a primary MLTC depends on tumor-derived IL-10. MLTC cultures (BALB/c ce
ADJ) were set up with 2 107 BALB/c spleen cells and 106 X-irradiated ADJ-PC-5 cells in the absence (closed bars) or presence (open
bars) of a mix of two IL-10-specific monoclonal antibodies (SXC-1 and SXC-2; 10/xg/ml each). Allogenic MLC cultures (CBA/J ce BALB/c)
were set up in the presence or absence of IL-10-specific antibodies with 2 107 CBA/J spleen cells and 107 X-irradiated BALB/c spleen
cells. The resulting cytotoxicity was measured on day 6 against ADJ-PC-5 (ADJ) cells and a syngeneic control B-cell tumor (A20).TC1/TC2 RESPONSES AGAINST A MURINE PLASMACYTOMA 335
detected in MLTC cultures nor in MLC cultures.
However, it must be mentioned that at least some
CD8 T-cell lines that were derived from a primary
MLTC by repeated in vitro stimulation with irradiated
ADJ-PC-5 cells produce substantial amounts of IL-4
but no IFN-T and aquire a full Tc2 phenotype (see
what follows).
All three features of the primary tumor-specific Tc
response, that is, the suppression by IFN-y and IL-12,
the dependence on IL-10, and the lack of IFN-y
production by the resulting tumor-specific Tc cells,
point toward a type-2 nature of the in vitro Tc
response against the tumor.
Characterization of Long-Term Cultivated ADJ-
PC-5-Specifi CD8 Tc Lines
In order to phenotypically characterize ADJ-PC-
5-specific Tc cells further, CD8 Tc lines were
generated from spleen cells of ADJ-PC-5-immunized
BALB/c mice or from spleen cells of naive BALB/c
mice that were stimulated with irradiated ADJ-PC-5
cells in a primary syngeneic MLTC. Nine of initially
24 CD8 ADJ-PC-5-specific Tc lines could be
cultivated over a period of more than 3 months;
among them, seven developed a quite homogeneous
phenotype. As shown in Table I, all of the nine lines
specifically lyse ADJ-PC-5 cells but not cells of
BALB/c unstim. BALB/c cx CBA/J BALB/c ADJ
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FIGURE 3 Flow cytometric detection of intracellular cytokines on a single-cell level. Living cells were isolated from MLTC or allogeneic
MLC cultures after day 5 of the culture period and stained for intracellular cytokines according to Materials and Methods. Both cytokine-
specific MoAb are of the same isotype and were used at the same concentrations. Thus, data for an isotype control antibody are not shown.
Percentages of the respective populations are indicated in the upper right quadrant of each plot.336 C. SPECHT et al.
TABLE Phenotypes of ADJ-PC-5-Specific Tc Lines
Line Preimmunization % specific cytotoxicity Cytokine production
Target E:T % CD8 V/3 usage IFN- 3/ IL-4
10:1 5:1 major V/3 % V/3/CD8 aCD3 aCD3
BTc 2 107 (7) ADJ 78 63 97 6 98 0 8,439 0 998
Meth. A 13 5
BTc 3 ADJ 56 33 88 6 99 0 1,717 0 22,579
Meth. A 0 0
BTc 4 5 106 (1) ADJ 42 20 90 6 94 0 31,129 0 1,030
Meth. A 0 0
BTc 5 5 106 (1) ADJ 58 47 68 6 90 0 13,311 0 692
Meth. A 18 11
BTc 6 5 106 (1) ADJ 72 56 95 6 34 0 27,760 0 977
Meth. A 13 10
BTc 7 ADJ 41 30 40 8.1/8.2 63 0 974 0 23,893
Meth. A 5 3
BTc 8 ADJ 55 28 95 8.1/8.2 76 0 3,500 0 0
Meth. A 0
0 BTc 9 ADJ 57 32 94 8.1/8.2 78 0 3,1200
Meth. A 0 0
BTc 14 ADJ 60 27 95 8.1/8.2 62 0 3,300 0 0
Meth. A 0 0
aTc lines were generated from spleen cells of naive or ADJ-PC-5 preimmunized BALB/c mice.bCytotoxicity of Tc lines was measured
against 104 ADJ-PC-5 or Meth A cells in a 6-hr 5Cr-release assay at the indicated effector: target ratios.CTotal percentage of CD8 within
the respective line.dDominant V/3 TcR type and percentage of T cells espressing this V/3 type among CD8 T cells.eT cells were cultivated
at a density of 106/ml for 2 days and stimulated with either immobilized aCD3 antibodies or left unstimulated.
syngeneic control tumors like the BALB/c fibro-
sarcoma Meth A, which expresses MHC class I
molecules at about the same density as ADJ-PC-5
cells. T cells of all lines were examined for the
expression of TcR V/3 elements 2, 3, 5.1, 5.2, 6, 7,
8.1, 8.2, 8.3, 9, 11, and 17a.
Four of these lines (BTc2, BTc3, BTc4, and BTc5)
consist almost entirely of V/36+CD8 cells, whereas
the majority of CD8 cells in lines BTc7, BTc8,
BTc9, and BTcl4 are of the V/38.1/8.2 phenotype.
CD8 cells of line BTc6 are 34% V/36+; the remaining
CD8 cells express lower percentages of other TcR
V/3 families. Early analysis of TcR expressed by the
unstable lines revealed that even these lines contained
CD8 T cells of the V/36 or V/38.1/8.2 type at
frequencies significantly higher than among naive
peripheral T cells (data not shown).
Lines BTc3 and BTc7, which were derived from a
primary MLTC, produce a type-2 cytokine spectrum
(IL-4) on stimulation, whereas the other lines produce
type-1 cytokines, including line BTc2, which was
derived from a hyperimmune BALB/c mouse, and
lines BTc4, BTc5, and BTc6, which were derived
from once preimmunized mice. The fact that at least
two out of five Tc lines derived from primary MLTC
cultures by repeated in vitro restimulation develop a
Tc2 phenotype in the absence of exogenous IL-4 or
IFN-y-specific monoclonal antibodies, is in con-
cordance with a type-2 nature of the primary in vitro
Tc response against the tumor.
Phenotypic Analysis of CD8 T Cells from ADJ-
PC-5 Immune BALB/c Mice
As demonstrated before, all ADJ-PC-5-specific Tc
lines derived from preimmunized BALB/c mice are
Tc cells, whereas some of the Tc lines derived from
primary MLTC cultures are Tc2 cells. Since the
phenotype, and especially the cytokine profile of
cultivated T cells can be strongly influenced by the
culture conditions, it had to be tested if a comparable
Tcl/Tc2 pattern could also be found among peri-
pheral T cells from ADJ-PC-5 immune BALB/c mice.
Table II shows the results from a three-color fluores-TC1/TC2 RESPONSES AGAINST A MURINE PLASMACYTOMA 337
TABLE II Flow Cytometric Analysis of in vivo Induced ADJ-PC-5-Specific Tc Cells
Tc induction % CD8 % V/36+/CD8 % IFN-y+/CD8 % IFN-y/CD8 V/36 % IL-4+/CD8
In Vivo
Spleen naive 13.5 9.5 0.3 0.3 0.06
Spleen immune 14.9 9.3 3.8 3.1 0.08
PEC naive 8.0 10.1 0.8 0.9 1,24
PEC immune 9.8 12.0 7.1 12.0 1.67
Spleen cells or PEC were pooled from three individual ADJ-PC-5 immune or naive BALB/c mice and analyzed by flow cytometry according
to Materials and Methods.
cence analysis of spleen cells and PEC from naive and
ADJ-PC-5 immune BALB/c mice stained for CD8,
V/36, IFN-y, and IL-4. Repeated immunization of
BALB/c mice with the tumor does not substantially
alter the total number of splenic CD8 or CD8+V/36
T cells, which is a main phenotype of ADJ-PC-
5-specifi Tc lines, but induces IFN-y production in a
small but significant fraction of CD8 and CD8+V/36
T cells. The data demonstrate that the actual percent-
age of ADJ-PC-5-specific Tc cells among CD8 or
CD8+V/36 T cells must be low, even in immune
mice. However, production of IFN-y by the respec-
tive cells identifies them as Tcl cells. Production of
IL-4 is only detectable in a small fraction of CD8-
spleen cells from immune mice, but not in CD8 cells.
Peritoneal T cells from, immune and naive BALB/c
mice display similar properties, as seen for splenic T
cells. As for spleen cells, immunization with the
tumor increases the percentage of IFN-y-producing
CD8 or CD8+V/36 T cells by a factor of about 10. A
relatively high percentage of peritoneal CD8 T cells
produces IL-4. However, this population of IL-
4-producing peritoneal CD8 T cells does not expand
during immunization, indicating that the tumor-
specific Tc response in the peritoneal cavity is a Tcl
response, too.
ADJ-PC-5-Specific Tcl Cells Are Potent
Suppressors of Tc Induction in a Primary ADJ-
PC-5-Specifi MLTC In Vitro
Since IFN-y is a suppressive factor for Tc induction
in a primary ADJ-PC-5-specific MLTC, we analyzed
whether this suppressive effect is also exerted by
ADJ-PC-5-specific Tcl cells. As shown in Table III,
a substantial amount of Tc suppression in a primary
MLTC is seen in the presence of even the lowest
numbers of X-irradiated ADJ-PC-5-specific Tc 1 cells.
The suppressive effect in this case must be due to
IFN-y, since addition of IFN-y-specific monoclonal
antibodies to the cultures can in part avoid suppres-
sion (Table III, Exp. III). Irradiation of the Tc cells
is necessary, because otherwise the cultures would be
overgrown by restimulated Tcl cells within a few
days, making an analysis of the primary in vitro Tc
response impossible. Suppression of the primary Tc
response by a rapid elimination of ADJ-PC-5 stimu-
lator cells can be excluded in the case of low numbers
of irradiated Tc cells, since at any time point almost
equal numbers of ADJ-PC-5 stimulator cells could be
visually detected in MLTC cultures, irrespective if
irradiated Tc cells were added or not. In contrast to
low numbers of irradiated Tcl cells, suppression by
high numbers of irradiated Tc 1 cells is not influenced
by IFN-y-specific mAb (data not shown). Suppression
of the primary in vitro Tc response in this case, or in
the presence of high numbers of irradiated Tc2 cells,
can be entirely related to a rapid elimination of ADJ-
PC-5 stimulator cells within the first hours of the
culture period. The data demonstrate that Tcl cells
can interfere with the generation of ADJ-PC-5-spe-
cifi Tc cells in a primary syngeneic MLTC using
IFN-y as a suppressor factor. Thus, these ADJ-PC-
5-specifi Tcl cells behave similarly to tumor-
induced suppressive T cells from ADJ-PC-5 tumor-
bearing mice (Pauels et al., 1996).
DISCUSSION
Although the BALB/c plasmacytoma ADJ-PC-5 is
highly immunogenic, tumor growth in syngeneic338 C. SPECHT et al.
TABLE III Suppression of ADJ-PC-5-Specific Tc Induction in a Primary MLTC by ADJ-PC-5-Specific Type-1 Tc Lines
Stimulator Anti-IFN- 3/ Type- Tc % specific
cytotoxicity against
ADJ-PC-5
100:1 50:1 25:1
Exp.
Exp. II
Exp. III
0 0 0
ADJ 46 40 15
ADJ BTc2(1 105 0 0 0
ADJ BTc2(5 105 0 0 0
0 0 0
ADJ 29 19 10
ADJ BTc4(1 105 0 0 0
ADJ BTc 4 (5 105) 0 0 0
ADJ 70 61 54
ADJ 20/xg/ml 70 64 40
ADJ BTc8(1 105 8 10
ADJ 20/xg/ml BTc 8 (1 105) 36 26 16
ADJ 5 g/ml BTc 8 (1 105) 4 9 8
Thirty-Gy X-irradiated type-1 Tc cells were added on day 0 at the indicated cell numbers to a primary ADJ-PC-5-specific MLTC containing
different concentrations of IFN-y-specific monoclonal antibodies. The resulting ADJ-PC-5-specific cytotoxicity was measured on day 6 in
a 5Cr-release assay at the indicated effector:target ratios.
BALB/c mice does not elicit a protective tumor-
specific Tc response, but induces a state of tumor-
specific tolerance. We could previously demonstrate
that the tumor induces a population of CD8 T cells
during early stages of tumorigenesis, which are able
to suppress a primary ADJ-PC-5-specific Tc response
in vitro through IFN-T (Pauels et al., 1996).
Recent data concerning Tc cells imply a functional
and phenotypical dichotomy among CD8 T cells
(LeGros and Erard, 1994; Sad et al., 1995), similar to
the one observed in CD4 Thl and Th2 cells. Since
suppressive T cells from tumor-tolerant mice and Tc
cells from tumor-immune mice are both CD8+, we
asked whether the failure of BALB/c mice to mount a
protective Tc response against a growing ADJ-PC-5
tumor might reflect the involvement of counteractive
CD8 Tc and Tc2 cells. To answer this question, the
phenotypes and cytokine profiles of ADJ-PC-5-spe-
cifi T cells had to be analyzed.
Long-term cultivated ADJ-PC-5-specific Tc cells
are CD8 and use TcR of the V/36 and V/38 types. The
exclusive CD8 phenotype of the lines is in accord-
ance with the finding that ADJ-PC-5 cells are MHC
class II negative (Becker et al., 1997). The majority of
the Tc lines produce high amounts of IFN-T but no or
only marginal amounts of IL-4 on stimulation, and
can thus be classified as Tcl cells (Sad et al., 1995).
Nevertheless, at least two of five ADJ-PC-5-specific
CD8 T-cell lines, which were derived from a primary
MLTC by repeated restimulation with X-irradiated
tumor cells, are IL-4-producing Tc2 cells. Whereas in
other experimental systems, the addition of high
amounts of IL-4 and blocking antibodies against IFN-
3/ is a prerequisite for the generation of antigen-
specific Tc2 lines (Sad et al., 1995), the exogenous
addition of immunomodulating cytokines or anti-
bodies against cytokines is not necessarily required
for the induction of tumor-specific Tc2 cells against
ADJ-PC-5 plasmacytoma cells. The driving force for
Tc2 differentiation in this case seems to be endo-
genous IL-10 produced by the tumor cells themselves,
since addition of blocking antibodies against IL-10 to
a primary MLTC can completely abrogate the induc-
tion of tumor-specific Tc cells (see what follows).
Since the cytokine phenotype of long-term cultivated
T-cell lines is strongly influenced by the culture
conditions, the observed numbers of Tcl and Tc2
lines must not necessarily reflect the participation of
both T-cell subsets during tumor-specific Tc
responses in situ. For this reason, we examined the
involvement of either of these T-cell subsets among
CD8 and CD8+V/36 T cells during ADJ-PC-TC1/TC2 RESPONSES AGAINST A MURINE PLASMACYTOMA 339
5-specific Tc responses in vivo and in vitro using
intracellular cytokine staining (CD8+V/36 is a major
phenotype of ADJ-PC-5-specific Tc lines).
ADJ-PC-5-specific Tc cells from immunized mice
are Tcl cells. This is proven by the exclusive
generation of ADJ-PC-5-specific Tcl lines from
preimmunized mice. Furthermore, immunization with
the tumor significantly increases the percentages of
IFN-y-producing CD8 and CD8+V/36 T cells
among spleen cells and PEC, as compared with naive
mice.
In contrast to in vivo induced ADJ-PC-5-specific
Tc cells, the in vitro Tc response against the tumor
shows Tc2 characteristics. This is demonstrated by a
lack of IFN-y production of the tumor-reactive Tc
cells, which are induced during a primary MLTC. It is
also confirmed by means of supplementation experi-
ments with exogenous cytokines, since the primary in
vitro Tc response against ADJ-PC-5 cells is enhanced
by IL-4, but suppressed by IFN-y and IL-12.
Furthermore, the primary in vitro Tc response against
ADJ-PC-5 is suppressed by irradiated Tcl cells via
IFN-T.
In this context, the Tcl cells behave similar to the
previously described CD8 suppressive T cells from
tumor-tolerant mice (Pauels et al., 1996). However,
these suppressive CD8 T cells did never show any
significant cytotoxicity against ADJ-PC-5 cells,
whereas the Tcl lines are potent tumor-specific Tc
cells. It is presently not clear if the suppressive T cells
in tumor-tolerant mice are Tc 1 cells that in situ occur
at frequencies too low to cause any substantial
cytotoxicity or if they are incompletely activated Tc
cells, which produce suppressive cytokines but are not
sufficiently activated for cytotoxicity.
IL-10 has been described as a cytotoxic T-cell
differentiation factor (Chang and Zlotnik, 1991), as
well as an inhibitor of CD8 cytotoxic T-cell
responses in primary allogenic MLC cultures (Bejar-
ano et al., 1992). Thus, the effects of IL-10 on CD8
T cells seem to depend on the kind of CD8 T-cell
response studied. In our experimental system, tumor-
derived IL-10 is an essential differentiation factor for
the induction of CD8 ADJ-PC-5-specific Tc cells,
since blocking of IL-10 in MLTC cultures by
monoclonal antibodies can completely abrogate the
tumor-specific Tc response.
Production of IL-10 is a general property of
malignancies of the B-lymphocyte lineage (Bost et
al., 1995). It has previously been shown for CD4 T
cells that IL-10, which is produced by Th2 cells, is a
potent inhibitor of Thl functions (Fiorentino et al.,
1989), whereas Thl cells are able to suppress Th2
cells via IFN-T (Gajewski and Fitch, 1988). It is also
known that Thl functions are drastically decreased in
mice bearing IL-10-producing plasma-cell tumors
(Ruzek and Mathur, 1995). Therefore, it is likely that
production of IL-10 by ADJ-PC-5 cells strongly
influences the CD8 Tc-cell response against the
tumor. In this context, high cell numbers of ADJ-PC-
5 cells, which are present in a MLTC produce
sufficiently high amounts of IL-10 to dictate a Tc2-
dominated response against the tumor in vitro. On the
other hand, low numbers of tumor cells, which are
present during early stages of tumorigenesis in vivo,
could result in a Tcl-dominated response due to a
lack of substantial amounts of IL-10. The same seems
to be true for mice that were weekly immunized with
high numbers or X-irradiated ADJ-PC-5 tumor cells.
In this case, the IL-10 might be rapidly cleared from
the surrounding of the tumor cells without being
further produced by the tumor cells that die from
irradiation.
Suppression via IFN-3, of the IL-10-driven Tc2
response against ADJ-PC-5 cells is the main reason
for the downregulation of the tumor-specific Tc
response in a primary MLTC by CD8 T cells from
tumor-treated mice. However, the question remains to
be answered, how an early response of IFN-y-
producing CD8 T cells during early stages of
tumorigeneses can omit the onset of a Tc1-dominated
response during the course of a subsequent immuniza-
tion with high numbers of tumor cells.
We are presently favoring the following model:
During early stages of tumorigenesis, when no
substantial amounts of IL-10 are present, the growing
tumor induces a transient tumor-specific Tcl
response. This early Tc response, which is not strong
enough to cause a regression of the tumor, is
subsequently stopped by tumor-derived IL- 10, when340 C. SPECHT et al.
the tumor mass increases. These Tc I cells must be in
some state of anergy, because a subsequent immun-
ization with high numbers of X-irradiated ADJ-PC-5
tumor cells can no longer induce a protective tumor-
specific Tc response, as it would be the case in naive
mice. The Tc 1 cells are likely to be anergized, but not
deleted by the tumor, since CD8 T cells from tumor-
bearing mice, or from mice that have been subjected
to a simulated tumor growth, can still suppress a Tc2-
dominated primary MLTC via IFN-y.
as hybridoma supernatant or as affinity-purified
material using Protein G sepharose (Pharmacia,
Uppsala, Sweden). Rat monoclonal antibodies against
IL-10 (SXC-1 and SXC-2, IgM; Mosmann et al.,
1990) were purified from hybridoma supernatants by
ammonium sulphate precipitation followed by ion-
exchange chromatoraphy on hydroxylapatite col-
umns.
MATERIALS AND METHODS
Mice and Tumors
Female BALB/c mice were aged 8 to 12 weeks at the
beginning of each experiment. The animals were
either purchased from Charles River (Sulzfeld, Ger-
many) or bred at our own animal facility. The
nonsecreting variant of the BALB/c plasmacytoma
ADJ-PC-5 (ADJ-PC-5-NS) (Blatt and Ha’fmovich,
1977), originally obtained from J. Ha’fmovich (Weiz-
mann Institute, Rehovot, Israel) was used as a model
tumor. The BALB/c fibrosarcoma Meth A (Old et al.,
1962), the DBA/2 plasmacytoma ULMC (Bosslet et
al., 1979), and the BALB/c B-cell lymphoma A20
(Kim et al., 1979) were used as control tumors in
some experiments.
Generation of Tumor-Induced Suppressive T
Cells by Tumor Growth Simulation
The in vivo induction of suppressive T cells by tumor
growth simulation has been previously described
(Haubeck and K61sch, 1982). Briefly, BALB/c mice
recieved daily intraperitoneal injections of exponen-
tially increasing numbers of 60-Gy X-irradiated ADJ-
PC-5 cells starting with eight cells on day 0.
According to the generation time of the tumor, doses
of injected tumor cells were doubled every day, until
mice had recieved 105 cells on day 16. Eight days
after the last treatment with ADJ-PC-5 cells, perito-
neal exudate cells (PEC) were collected by a perito-
neal lavage and fractionated into adherent and
nonadherent cells by overnight incubation on plastic
dishes at 37C in MLC medium. Mice in which tumor
growth was simulated by the preceding protocol are
subsequently denoted "tumor-treated."
Media
Dulbecco’s modified Eagle’s medium, containing
penicillin (50 U/ml), streptomycin (50 /xg/ml), L-
glutamine (2 mM), 2-mercaptoethanol (5 105 M),
nonessential amino acids, 10% FCS, and additionally
3.5 g/1 glucose (referred to as MLC medium), was
used for most experiments. Hank’s balanced salt
solution (BSS) was used as washing medium.
Monoclonal Antibodies
Monoclonal rat antibodies specific for murine IFN-y
(R4-6A2, IgG1; (Spitalny and Havell, 1984), V/36
(44-22-1, IgG2a; (Acha-Orbea et al., 1985), and
V/38.1 (KJ 16, IgG2a; Haskins et al., 1984) were used
Generation and Culture of ADJ-PC-5-Specific Tc
Lines
Tumor-specific Tc lines were generated by weekly in
vitro restimulations of 1 105 spleen cells or
peritoneal exudate cells from naive or ADJ-PC-5
preimmunized BALB/c mice with 5 106 X-
irradiated BALB/c spleen cells and 2 105 X-
irradiated ADJ-PC-5 cells in 10 ml MLC medium.
After the second to fifth restimulation, most Tc
cultures were supplemented with 5% of an IL-2/IFN-
y containing supernatant from Con-A-stimulated rat
spleen cells (CM) or with 5 U/ml recombinant human
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Mixed Lymphocyte Tumor Cell Culture (MLTC)
ADJ-PC-5-specific Tc cells were generated in a
primary syngeneic MLTC from spleen cells of naive
mice as previously described (Haubeck and K61sch,
1982). Briefly, 2 107 BALB/c spleen cells were
cultured with 106 60-Gy X-irradiated ADJ-PC-5
cells in 10 ml ofMLC medium for 6 days. Thereafter,
cells were harvested and tested in a 6-hr 51Cr-release
assay for specific cytotoxicity (Haubeck and K61sch,
1982). In some experiments, the medium used for Tc
induction was supplemented with recombinant IL-4,
IL- 12, or IFN-3/or monoclonal antibodies against IL-
l0.
Sources and Measurement of Cytokines
Recombinant mouse IL-4 and recombinant rat IFN-y
were purchased from Hycult Biotechnology (Uden,
The Netherlands), whereas recombinant mouse IL-12
was kindly provided by Frank J. Podlasky (Hoff-
mann-LaRoche, Nutley, NJ). IL-4, IFN-T, and IL-10
were determined by means of a sandwich ELISA
using 2A5.7 (Sander et al., 1993), and biotinylated
XT1 monoclonal anti-bodies for IL-10, R4-6A2
(Spitalny and Havell, 1984), and biotinylated XMG
1.2 for IFN-y, 11B 11 (Ohara and Paul, 1985), and
biotinylated BVD6-24G2 for IL-4. All biotinylated
monoclonal antibodies were purchased from Phar-
mingen (San Diego).
In Vitro Assay for T-Cell-Mediated Suppression
To test their suppressive capacity, nonadherent PEC
from naive and tumor-treated mice, or 30-Gy X-
irradiated ADJ-PC-5-specific Tc cells were added to
an ADJ-PC-5-specific MLTC (as described earlier) at
day 0 of culture. After 6 days, specific cytotoxic
activity against ADJ-PC-5 cells was measured in a
6-hr 51Cr-release assay and compared with the
cytotoxicity from cultures without added T cells. For
some experiments, IFN-y-specific monoclonal anti-
bodies were added to the cultures at various con-
centrations.
Flow Cytometric Analysis
For flow cytometric analysis of surface markers on
tumor-specific T cells, cells were harvested and
washed with BSS. For two-parameter analysis of V/3
expression on CD8 ADJ-PC-5-specific Tc lines, cells
were incubated with FITC-coupled, V/3-specific, and
PE-coupled CD8-specific monoclonal antibodies
(Pharmingen, San Diego). All washing and incubation
steps were performed with ice-cold MLC medium
containing 0.1% NAN3. Labeled cells were analyzed
using a FACScan flow cytometer (Becton-Dickinson,
Heidelberg). Prior to flow cytometric analysis, sam-
ples were incubated with 10/zg/ml propidiumiodide
to discriminate dead cells from living cells.
Detection of Intracellular Cytokines
Staining of intracellular cytokines was performed
according to the saponin/monensin method, as
described elsewhere (Jung et al., 1993). Briefly,
spleen cells, peritoneal exudate cells, or cells from
primary MLTC or MLC cultures were purified by
centrifugation over a discontinuous Ficoll gradient
(Pharmacia, Uppsala, Sweden). Purified cells were
stimulated with 10 ng/ml PMA (Serva, Heidelberg)
and /M ionomycin (Sigma, Deisenhofen, Ger-
many) in the presence of 1/xM monensin (Sigma) for
4 hr. Subsequently, cells were fixed with 4% paraf-
ormaldehyde in BSS for 15 rain on ice. Intracellular
cytokines were stained with biotinylated mAb against
murine IFN-T or murine IL-4 (both from Pharmingen)
followed by Streptavidin-PE. All incubation steps
were performed for 30 rain at 4C. The medium used
for incubation and washing steps was BSS containing
5% FCS and 0.1% saponin (Fluka, Neu-Ulm, Ger-
many) to cause reversible pore formation. Immedi-
ately before flow cytometric analysis, cells were
extensively washed with BSS without saponin to
reverse pore formation and counterstained for 30 min
with CyChrome-coupled mAb against CD8 and
FITC-coupled mAb against V/36 (both from Pharmin-
gen). Cytokine expression was evaluated with a
FACScan flow cytometer (Becton-Dickinson).342 C. SPECHT et al.
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